Info: Read More
  • 中药标准品生产商,产品定制服务
  • 育亨宾

    Yohimbine

    育亨宾
    产品编号 CFN90147
    CAS编号 146-48-5
    分子式 = 分子量 C21H26N2O3 = 354.44
    产品纯度 >=98%
    物理属性 Cryst.
    化合物类型 Alkaloids
    植物来源 The peels of Corynante yohimbe.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    育亨宾 CFN90147 146-48-5 10mg QQ客服:1457312923
    育亨宾 CFN90147 146-48-5 20mg QQ客服:1457312923
    育亨宾 CFN90147 146-48-5 50mg QQ客服:1457312923
    育亨宾 CFN90147 146-48-5 100mg QQ客服:1457312923
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • University of Virginia (USA)
  • Donald Danforth Plant Science Center (USA)
  • Leibniz-Institut für Pflanzenbiochemie (IPB) (Germany)
  • University of Helsinki (Finland)
  • Complutense University of Madrid (Spain)
  • Max-Planck-Insitut (Germany)
  • The Vancouver Prostate Centre (VPC) (Canada)
  • Charles Sturt University (Denmark)
  • Universidad Industrial de Santander (Colombia)
  • The Institute of Cancer Research (United Kingdom)
  • Worcester Polytechnic Institute (USA)
  • Siksha O Anusandhan University (India)
  • National Cancer Institute (USA)
  • University of Otago (New Zealand)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Anal Biochem.2019, 569:10-15
  • Planta Med.2019, 85(9-10):766-773
  • Appl. Sci. 2021, 11(22),10569
  • Phytother Res.2019, 33(5):1490-1500
  • Plos One.2019, 15(2):e0220084
  • Biomolecules.2023, 13(2):227.
  • Nanjing University of Chinese Medicine2022, 345930.
  • Int J Vitam Nutr Res.2022, doi: 10.1024.
  • Phytother Res.2016, 30(12):2020-2026
  • Antioxidants (Basel).2020, 9(6):466.
  • Analytical methods2019, 11(6)
  • Antioxidants (Basel).2022, 11(12):2411.
  • Nat Prod Sci.2014, 20(3):182-190
  • ACS Omega2020, 5,33,20825-20830
  • Antiviral Res.2013, 98(3):386-93
  • J Korean Soc Food Sci Nutr2023, 52(11):1101-1110
  • J Ethnopharmacol.2017, 206:327-336
  • China Pharmacy2015, 26(27)
  • Heliyon.2023, 9(12):e22932.
  • National Academy Science Letters2023, s40009.
  • Anticancer Res.2014, 34(7):3505-9
  • Int J Oncol.2016, 49(4):1497-504
  • The Journal of Korean Medicine2022, 43(3): 79-93.
  • ...
  • 生物活性
    Description: Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM. Yohimbine may augment extinction learning without significant side effects, and as a therapeutic augmentation strategy for exposure therapy in social anxiety disorder. Yohimbine can be used as antagonistic agents against medetomidine-induced diuresis in healthy cats; it inhibits ATP-sensitive K+ channels in mouse pancreatic beta-cells.
    Targets: alpha 2-adrenergic receptor | ATPase | Potassium Channel
    In vitro:
    Br J Pharmacol. 1990 Sep;101(1):115-20.
    Phentolamine and yohimbine inhibit ATP-sensitive K+ channels in mouse pancreatic beta-cells.[Pubmed: 2282453 ]
    1. The effects of phentolamine and yohimbine on adenosine 5'-triphosphate (ATP)-sensitive K+ channels were studied in normal mouse beta-cells.
    METHODS AND RESULTS:
    2. In the presence of 3 mM glucose, many ATP-sensitive K+ channels are open in the beta-cell membrane. Under these conditions, phentolamine inhibited 86Rb efflux from the islets. This inhibition was faster with 100 than with 20 microM phentolamine but its steady-state magnitude was similar with both concentrations. Yohimbine (20-100 microM) also inhibited the efflux rate but was not as potent as phentolamine. 3. In the presence of 6 mM glucose, most ATP-sensitive K+ channels are closed in the beta-cell membrane. Their opening by 100 microM diazoxide caused a marked acceleration of 86Rb efflux from the islets. This acceleration was almost entirely prevented by 20 microM phentolamine. It was barely affected by 20 microM yohimbine and reduced by 50% by 100 microM yohimbine. 4. ATP-sensitive K+ currents were studied in single beta-cells by the whole cell patch-clamp technique. Phentolamine (20-100 microM) caused a progressive but almost complete and irreversible inhibition of the current. The effects of yohimbine were faster but smaller; the inhibition was still incomplete with 100 microM yohimbine. 5. The increase in ATP-sensitive K+ current produced by 100 microM diazoxide was prevented by 100 microM phentolamine but only partially attenuated by 100 microM yohimbine.
    CONCLUSIONS:
    6. It is concluded that phentolamine inhibits ATP-sensitive K+ channels in pancreatic beta-cells. This novel effect of phentolamine resembles that of hypoglycaemic sulphonylureas. It may account for previously unexplained effects of the drug. These observations also call for reinterpretation of many studies in which phentolamine was used as an allegedly specific blocker of alpha-adrenoceptors.
    In vivo:
    Biol Psychiatry. 2014 Jun 1;75(11):840-6.
    Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial.[Pubmed: 24237691]
    Preclinical and clinical trials suggest that yohimbine may augment extinction learning without significant side effects. However, previous clinical trials have only examined adults with specific phobias. Yohimbine has not yet been investigated in the augmentation of exposure therapy for other anxiety disorders.
    METHODS AND RESULTS:
    Adults (n = 40) with a DSM-IV diagnosis of social anxiety disorder were randomized to placebo or yohimbine HCl (10.8 mg) 1 hour before each of four exposure sessions. Outcome measures were collected at baseline, each treatment session, posttreatment, and 1-month follow-up. Yohimbine was well tolerated. Yohimbine augmentation, relative to placebo augmentation, resulted in faster improvement and better outcomes on self-report measures of social anxiety disorder severity (Liebowitz Social Anxiety Scale, d = .53) and depressed mood severity (Beck Depression Inventory, d = .37) but not on the clinician-rated measures (Clinical Global Impressions-Severity Scale, d = .09; Clinical Global Impressions-Improvement Scale, d = .25). Between-group differences on the Liebowitz Social Anxiety Scale were moderated by the level of fear reported at the end of an exposure exercise (end fear), such that the advantage of yohimbine over placebo was only evident among patients who reported low end fear.
    CONCLUSIONS:
    The results provide moderate support for yohimbine as a therapeutic augmentation strategy for exposure therapy in social anxiety disorder, one that may be especially effective when coupled with successful exposure experiences. Beneficial effects for yohimbine were readily evident for self-report measures but not for clinician-rated outcomes of social anxiety severity and improvement.
    Psychopharmacology (Berl). 2007 Dec;195(3):345-55.
    The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.[Pubmed: 17705061 ]
    Yohimbine is an alpha-2 adrenoreceptor antagonist that provokes stress- and anxiety-like responses in both humans and laboratory animals. In rats, yohimbine increases operant alcohol self-administration and reinstates alcohol seeking. In this study, we assess whether these effects of yohimbine are attenuated by systemic injections of the corticotrotropin-releasing factor 1 (CRF1) receptor antagonist antalarmin.
    METHODS AND RESULTS:
    In Exp. 1, we trained rats to lever press for alcohol solutions (12% w/v, 1 h/day) over several weeks; during training, the response requirement was increased from a fixed-ratio-1 (FR-1) to a fixed-ratio-3 (FR-3) reinforcement schedule. We then tested the effect of antalarmin (10 or 20 mg/kg) on yohimbine (1.25 mg/kg)-induced increases in operant alcohol self-administration (FR-3 reinforcement schedule). Subsequently, we assessed the effect of antalarmin on yohimbine-induced increases in plasma corticosterone levels in the previously self-administering rats. In Exp. 2, we trained the rats to self-administer alcohol as in Exp. 1, and after extinction of the alcohol-reinforced lever responding over 13 days, we tested antalarmin's effect on yohimbine-induced reinstatement of alcohol seeking. Yohimbine increased operant alcohol self-administration and reinstated alcohol seeking after extinction. These effects of yohimbine were attenuated by antalarmin. Antalarmin injections in the absence of yohimbine had no effect on either operant alcohol self-administration or extinction responding. Antalarmin had no effect on yohimbine-induced corticosterone release in alcohol-experienced rats.
    CONCLUSIONS:
    These results suggest that extrahypothalamic CRF1 receptors are involved in the effect of yohimbine on operant alcohol self-administration and on relapse to alcohol seeking and support the notion that CRF1 receptor antagonists should be considered in alcohol addiction treatment.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.8214 mL 14.1068 mL 28.2135 mL 56.427 mL 70.5338 mL
    5 mM 0.5643 mL 2.8214 mL 5.6427 mL 11.2854 mL 14.1068 mL
    10 mM 0.2821 mL 1.4107 mL 2.8214 mL 5.6427 mL 7.0534 mL
    50 mM 0.0564 mL 0.2821 mL 0.5643 mL 1.1285 mL 1.4107 mL
    100 mM 0.0282 mL 0.1411 mL 0.2821 mL 0.5643 mL 0.7053 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    利血平氮氧化物; Reserpin N-oxide CFN92583 474-48-6 C33H40N2O10 = 624.7 5mg QQ客服:215959384
    18-β-羟基-3-表-α-育亨宾; 18-Beta-hydroxy-3-epi-alpha-yohimbine CFN92610 81703-06-2 C21H26N2O4 = 370.5 5mg QQ客服:1413575084
    利血平; Reserpine CFN98112 50-55-5 C33H40N2O9 = 608.69 20mg QQ客服:2056216494
    羧酯利血平; Syrosingopine CFN98542 84-36-6 C35H42N2O11 = 666.71 5mg QQ客服:3257982914
    异柯楠碱; Isorauhimbine CFN98762 483-09-0 C21H26N2O3 = 354.5 5mg QQ客服:1413575084
    β-育亨宾; beta-Yohimbine CFN98921 549-84-8 C21H26N2O3 = 354.5 5mg QQ客服:1413575084
    α-育亨宾; alpha-Yohimbine CFN99400 131-03-3 C21H26N2O3 = 354.5 5mg QQ客服:1413575084
    盐酸育亨宾; Yohimbine Hydrochloride CFN99511 65-19-0 C21H26N2O3 HCL = 390.91 20mg QQ客服:2159513211
    常绿钩吻碱; Sempervirine CFN97173 6882-99-1 C19H16N2 = 272.4 5mg QQ客服:2056216494
    别育享宾; Allo-Yohimbine CFN92577 522-94-1 C21H26N2O3 = 354.5 5mg QQ客服:1413575084

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产